Federal organizers said on Friday that the deficiency of Ozmebek and Wugovi, who was present for more than two years, had been dissolved, as the supply of diabetes and folk diabetes continues to improve.
The Food and Drug Administration said that the pharmaceutical maker Novo Nordsek can meet the current and future demand in the United States. But patients may still see some symptom disorders, as drugs are transferred from the manufacturer to distributors and then to pharmacies.
The drugs have been injected into a shortage since 2022.
In December, the Food and Drug Administration (FDA) announced that the shortage of Zepbound and mounjaro treatments from another drug maker, Eli Lilly and Co. It has also been resolved. Zepbound has been approved to treat obesity and is approved by mounjaro for diabetes. They use the same active ingredient, Terzopatide.
The US decision notification comes nearly two months after Canada, which was also suffering from a lack of OzemPIC and Whost Weight medicines, was also witnessing on January 27 that its supplies settled.
Get weekly health news
Receive the latest medical news and health information provided to you every Sunday.
“Ozmpic and Wegovy are available throughout Canada, and we do not expect any shortage of the future at this time,” said a spokesman for Novo Nordisk Canada in a statement.
OzemPIC, for diabetes, Wegovy, for weight loss, is used by the active ingredient semaglutide.
All four drugs are part of the GLP-1 category of treatments that have shown unprecedented results to help people get rid of weight by reducing appetite and increasing feelings of fullness.
Sales have increased for drugs in recent years. But the deficiency made access to these drugs represents a challenge for many patients as drug makers raced to increase production.
And copied 2025 Canadian press
